Adaptive Biotechnologies Corporation (ADPT) Stock Score, Valuation & Financial Research
Adaptive Biotechnologies Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for ADPT
Adaptive Biotechnologies Corporation currently has a Wall Street Score of 19/100. The stored market price is $27.67. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Adaptive Biotechnologies Corporation does
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chron
ADPT financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $27.67
- Market capitalization:
- $4.43B
- Revenue:
- $308.1M
- Net income:
- $-63.9M
- Free cash flow:
- $-48.9M
- Cash:
- $169.9M
- Total debt:
- $410.5M
- EPS:
- -0.41
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 32/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-48.9M, showing cash burn in the current stored period.
- The balance sheet shows $169.9M of cash versus $410.5M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ADPT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.